Compounds > 9-aminocamptothecin
Page last updated: 2024-08-25

9-aminocamptothecin and Prostatic Neoplasms

9-aminocamptothecin has been researched along with Prostatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lehr, JE; Naik, H; Pienta, KJ1
Cooper, MR; de Souza, PL; Imondi, AR; Myers, CE1

Other Studies

2 other study(ies) available for 9-aminocamptothecin and Prostatic Neoplasms

ArticleYear
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
    Urology, 1996, Volume: 48, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Estramustine; Humans; Male; Prostatic Neoplasms; Rats

1996
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:2

    Topics: Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lactones; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured

1997